Most cited documents in this series:

Year	Title	Cited
2006	The relationship between health care expenditure and health outcomes RePEc:spr:eujhec:v:7:y:2006:i:1:p:7-18 [Citation Analysis]	14
2003	Economic burden of obesity and its complications in Germany RePEc:spr:eujhec:v:4:y:2003:i:4:p:248-253 [Citation Analysis]	8
2004	Economic valuation of informal care RePEc:spr:eujhec:v:5:y:2004:i:1:p:36-45 [Citation Analysis]	8
2004	Measuring and comparing the (in)efficiency of German and Swiss hospitals RePEc:spr:eujhec:v:5:y:2004:i:3:p:216-226 [Citation Analysis]	7
2005	Spatial competition for quality in the market for hospital care RePEc:spr:eujhec:v:6:y:2005:i:2:p:131-135 [Citation Analysis]	6
2007	Economic aspects of the new Spanish laws on pharmaceutical preparations RePEc:spr:eujhec:v:8:y:2007:i:3:p:297-300 [Citation Analysis]	6
2006	Price regulation and generic competition in the pharmaceutical market RePEc:spr:eujhec:v:7:y:2006:i:3:p:204-211 [Citation Analysis]	6
2007	Risk adjustment policy options for casemix funding: international lessons in financing reform RePEc:spr:eujhec:v:8:y:2007:i:3:p:195-212 [Citation Analysis]	6
2007	Risk-adjusted capitation payments: how well do principal inpatient diagnosis-based models work in the German situation? Results from a large data set RePEc:spr:eujhec:v:8:y:2007:i:1:p:31-39 [Citation Analysis]	5
2004	Economic growth, longevity and the epidemiological transition RePEc:spr:eujhec:v:5:y:2004:i:2:p:166-174 [Citation Analysis]	5
2004	An empirical analysis of the demand for physician services across the European Union RePEc:spr:eujhec:v:5:y:2004:i:2:p:150-165 [Citation Analysis]	5
2005	The “Essential Levels of Care” in Italy: when being explicit serves the devolution of powers RePEc:spr:eujhec:v:6:y:2005:i:1:p:46-52 [Citation Analysis]	5
2005	An empirical analysis of tobacco addiction in Italy RePEc:spr:eujhec:v:6:y:2005:i:3:p:233-243 [Citation Analysis]	4
2006	Alcohol-related mortality, drinking behavior, and business cycles RePEc:spr:eujhec:v:7:y:2006:i:3:p:212-217 [Citation Analysis]	4
2004	What reimbursement for coronary revascularization with drug-eluting stents? RePEc:spr:eujhec:v:5:y:2004:i:4:p:309-316 [Citation Analysis]	4
2010	The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany RePEc:spr:eujhec:v:11:y:2010:i:3:p:267-277 [Citation Analysis]	3
2005	A ‘new and improved’ EQ-5D valuation questionnaire? RePEc:spr:eujhec:v:6:y:2005:i:1:p:73-82 [Citation Analysis]	3
2011	Ageing and health care expenditure in EU-15 RePEc:spr:eujhec:v:12:y:2011:i:5:p:469-478 [Citation Analysis]	3
2003	Scale of reference bias and the evolution of health RePEc:spr:eujhec:v:4:y:2003:i:3:p:176-183 [Citation Analysis]	3
2007	Foreign direct investment in the health care sector and most-favoured locations in developing countries RePEc:spr:eujhec:v:8:y:2007:i:4:p:305-312 [Citation Analysis]	3
2006	Tests of stationarity and cointegration of health care expenditure and gross domestic product RePEc:spr:eujhec:v:7:y:2006:i:4:p:285-289 [Citation Analysis]	3
2009	Factors affecting nurses’ decision to get the flu vaccine RePEc:spr:eujhec:v:10:y:2009:i:2:p:227-231 [Citation Analysis]	3
2011	Incentives in primary care and their impact on potentially avoidable hospital admissions RePEc:spr:eujhec:v:12:y:2011:i:4:p:297-309 [Citation Analysis]	3
2010	In which ways do unhealthy people older than 50 exit the labour market in France? RePEc:spr:eujhec:v:11:y:2010:i:2:p:127-140 [Citation Analysis]	3
2005	Defining the “Health Benefit Basket” in nine European countries RePEc:spr:eujhec:v:6:y:2005:i:1:p:2-10 [Citation Analysis]	3
2004	Economic evidence in multiple sclerosis: a review RePEc:spr:eujhec:v:5:y:2004:i:1:p:s54-s62 [Citation Analysis]	3
2005	Reimbursement and clinical guidance for pharmaceuticals in Sweden RePEc:spr:eujhec:v:6:y:2005:i:3:p:274-279 [Citation Analysis]	3
2005	Can economic evaluations be made more transferable? RePEc:spr:eujhec:v:6:y:2005:i:4:p:334-346 [Citation Analysis]	3
2003	Should one use smokeless tobacco in smoking cessation programs? RePEc:spr:eujhec:v:4:y:2003:i:4:p:263-270 [Citation Analysis]	3
2006	Fixed budgets as a cost containment measure for pharmaceuticals RePEc:spr:eujhec:v:7:y:2006:i:1:p:37-45 [Citation Analysis]	3
2006	Determinants of household health expenditure on western institutional health care RePEc:spr:eujhec:v:7:y:2006:i:3:p:195-203 [Citation Analysis]	3
2006	Costs and quality of life of multiple sclerosis in Germany RePEc:spr:eujhec:v:7:y:2006:i:02:p:34-44 [Citation Analysis]	2
2010	A French approach to cost-effectiveness analysis? RePEc:spr:eujhec:v:11:y:2010:i:6:p:521-523 [Citation Analysis]	2
2009	Do quality-adjusted life years take account of lost income? Evidence from an Australian survey RePEc:spr:eujhec:v:10:y:2009:i:1:p:103-109 [Citation Analysis]	2
2008	Procedures and methods of benefit assessments for medicines in Germany RePEc:spr:eujhec:v:9:y:2008:i:1:p:5-29 [Citation Analysis]	2
2010	Optimal savings and health spending over the life cycle RePEc:spr:eujhec:v:11:y:2010:i:4:p:355-365 [Citation Analysis]	2
2006	Costs and quality of life of multiple sclerosis in Sweden RePEc:spr:eujhec:v:7:y:2006:i:02:p:75-85 [Citation Analysis]	2
2006	Costs and quality of life of multiple sclerosis in Germany RePEc:spr:eujhec:v:7:y:2006:i:2:p:34-44 [Citation Analysis]	2
2009	Guidelines for completing the EURONHEED transferability information checklists RePEc:spr:eujhec:v:10:y:2009:i:2:p:157-165 [Citation Analysis]	2
2004	Dynamic competition in pharmaceuticals RePEc:spr:eujhec:v:5:y:2004:i:2:p:175-182 [Citation Analysis]	2
2010	The impact of missing data in the estimation of concentration index: a potential source of bias RePEc:spr:eujhec:v:11:y:2010:i:3:p:255-266 [Citation Analysis]	2
2004	Out-patient drug policy by clinical assessment rather than financial constraints? RePEc:spr:eujhec:v:5:y:2004:i:3:p:274-277 [Citation Analysis]	2
2009	Hybrid risk adjustment for pharmaceutical benefits RePEc:spr:eujhec:v:10:y:2009:i:3:p:299-308 [Citation Analysis]	2
2006	Time for a common standard for cost-effectiveness in Europe? RePEc:spr:eujhec:v:7:y:2006:i:4:p:223-224 [Citation Analysis]	2
2007	Patients’ willingness to pay for electronic communication with their general practitioner RePEc:spr:eujhec:v:8:y:2007:i:2:p:105-110 [Citation Analysis]	2
2005	Spanish health benefits for services of curative care RePEc:spr:eujhec:v:6:y:2005:i:1:p:66-72 [Citation Analysis]	2
2011	Discrimination in waiting times by insurance type and financial soundness of German acute care hospitals RePEc:spr:eujhec:v:12:y:2011:i:5:p:405-416 [Citation Analysis]	2
2010	Health insurance for the poor: impact on catastrophic and out-of-pocket health expenditures in Mexico RePEc:spr:eujhec:v:11:y:2010:i:5:p:437-447 [Citation Analysis]	2
2007	Variations in activity and practice patterns: a French study for GPs RePEc:spr:eujhec:v:8:y:2007:i:3:p:225-236 [Citation Analysis]	2
2005	Validating the EQ-5D with time trade off for the German population RePEc:spr:eujhec:v:6:y:2005:i:2:p:124-130 [Citation Analysis]	2

Citing documents used to compute impact factor 18:

Year	Title	See
2011	Informality and the expansion of social protection programs RePEc:pra:mprapa:35073	[Citation Analysis]
2011	Effect of universal health coverage on marriage, cohabitation and labor force participation RePEc:pra:mprapa:35074	[Citation Analysis]
2011	What values do the public want their health care systems to use in evaluating technologies? RePEc:spr:eujhec:v:12:y:2011:i:4:p:285-288	[Citation Analysis]
2011	Empirical Essays in Health and Education Economics RePEc:lmu:dissen:13187	[Citation Analysis]
2011	Endogenous lifetime, accidental bequests and economic growth RePEc:pra:mprapa:34647	[Citation Analysis]
2011	Evaluating Hospital Efficiency Adjusting for Quality Indicators: an Application to Portuguese NHS Hospitals RePEc:por:fepwps:435	[Citation Analysis]
2011	Relative effectiveness and the European pharmaceutical market RePEc:spr:eujhec:v:12:y:2011:i:2:p:97-102	[Citation Analysis]
2011	Occupational inequalities in health expectancies in France in the early 2000s: Unequal chances of reaching and living retirement in good health RePEc:dem:demres:v:25:y:2011:i:12	[Citation Analysis]
2011	Co-Payment Exemptions and Reference Prices: an Empirical Study of Pharmaceutical Prices in Germany RePEc:yor:hectdg:11/18	[Citation Analysis]
2011	Cross-National Evidence on Generic Pharmaceuticals: Pharmacy vs. Physician-Driven Markets RePEc:nbr:nberwo:17226	[Citation Analysis]
2011	From Rags to Riches? Immigration and Poverty in Spain RePEc:kap:poprpr:v:30:y:2011:i:5:p:661-676	[Citation Analysis]
2011	The Effect of Prenatal Stress on Birth Weight: Evidence from the al-Aqsa Intifada RePEc:iza:izadps:dp5535	[Citation Analysis]
2011	The Effect of Prenatal Stress on Birth Weight: Evidence from the al-Aqsa Intifada RePEc:diw:diwwpp:dp1108	[Citation Analysis]
2011	Estimates of patient costs related with population morbidity: can indirect costs affect the results? RePEc:spr:eujhec:v:12:y:2011:i:4:p:289-295	[Citation Analysis]
2011	Explaining primary healthcare pharmacy expenditure using classification of medications for chronic conditions RePEc:eee:hepoli:v:103:y:2011:i:1:p:9-15	[Citation Analysis]
2011	Largely ignored: the impact of the threshold value for a QALY on the importance of a transferability factor RePEc:spr:eujhec:v:12:y:2011:i:5:p:397-404	[Citation Analysis]
2011	Comparing top-down and bottom-up costing approaches for economic evaluation within social welfare RePEc:spr:eujhec:v:12:y:2011:i:5:p:445-453	[Citation Analysis]
2011	Health care prioritization in ageing societies: Influence of age, education, health literacy and culture RePEc:eee:hepoli:v:100:y:2011:i:2:p:219-233	[Citation Analysis]

Cites in year: CiY